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The role of invariant natural killer
T cells in dendritic cell licensing,
cross-priming, and memory
CD8+ T cell generation
Catherine Gottschalk, Elisabeth Mettke and Christian Kurts*
Institute of Experimental Immunology, Rheinische Friedrich-Wilhelms-University of Bonn, Bonn, Germany
New vaccination strategies focus on achieving CD8+ T cell (CTL) immunity rather than
on induction of protective antibody responses. While the requirement of CD4+ T (Th)
cell help in dendritic cell (DC) activation and licensing, and in CTL memory induction
has been described in several disease models, CTL responses may occur in a Th cell
help-independent manner. Invariant natural killer T cells (iNKT cells) can substitute for
Th cell help and license DC as well. iNKT cells produce a broad spectrum of Th1 and
Th2 cytokines, thereby inducing a similar set of costimulatory molecules and cytokines in
DC. This form of licensing differs from Th cell help by inducing other chemokines, while
Th cell-licensed DCs produce CCR5 ligands, iNKT cell-licensed DCs produce CCL17,
which attracts CCR4+ CD8+ T cells for subsequent activation. It has recently been shown
that iNKT cells do not only enhance immune responses against bacterial pathogens or
parasites but also play a role in viral infections. The inclusion of iNKT cell ligands in
influenza virus vaccines enhanced memory CTL generation and protective immunity in
a mouse model. This review will focus on the role of iNKT cells in the cross-talk with
cross-priming DC and memory CD8+ T cell formation.
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Classification of Natural Killer T Cells
Natural killer T cells (NKT cells) are a subset of lymphocytes with innate and adaptive immune
functions, for example, in tumor and anti-infectious defense (1). Their TCR can be either semi-
invariant and encoded by a germline Valpha gene [type I invariant natural killer T cells (iNKT cells)]
or may react against the self-antigen sulphatide using an oligoclonal TCR (type II NKT cells) (2–4).
This review focusses on iNKT cells in dendritic cell (DC) licensing and T cell activation leading to
a sustained memory response.
Invariant natural killer T cells respond to the marine sponge (Agelas mauritianus)-derived glycol-
ipid alpha-galactosylceramide (αGalCer) presented by the non-polymorphic CD1d molecule and
respond by rapidly producing various cytokines (5, 6). Mostly studied in mice, they represent about
0.5% of T cells in the blood, 2% in secondary lymphatic organs, and over 30% of T cells in the liver.
During inflammation and infection, iNKT cell numbers can strongly increase in numerous organs,
e.g., the pancreas in type I diabetes or the lung in asthma (7, 8). In human blood, only 0.1–0.2%
of T cells are iNKT cells, with 5 lower numbers than in mice (9). Recently, iNKT cells came into
focus as promising targets for the development of vaccine adjuvants and immunotherapies, mostly
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3791
Gottschalk et al. NKT cells in cross-priming
TABLE 1 | Summary of iNKT cell activation studies in treatment of different diseases.
Therapeutic target Species studied Outcome Reference, remarks
Viral and bacterial
infections
Human, mouse Effective vaccination in mice; oral and nasal route
possible; no clear effect on chronic viral infections in
clinical trials shown
(12–21)
Parasites and fungi Mouse Enhanced vaccine effects in mice (10, 22–24)
αGalCer analogs were used in Ref. (10) (7DW8–5) and
Ref. (20) (α-C-GalCer) for NKT cell activation
Tumors Human, mouse Enhanced tumor protection and rejection in mice; clinical
trials show only moderate effects in humans
(11, 14, 24–39)
Antigen-pulsed DC were transferred in Ref. (32), no
αGalCer or analog was added.
αGalCer and α-C-GalCer were tested for tumor therapy
in Ref. (34)
Autoimmune
diseases
Mouse αGalCer dose-dependent amelioration or aggravation of
autoimmune diseases; NKT cell hypo-responsiveness
involved in some cases
(8, 40–52)
Ref. (43) used OCH, a sphingosine-truncated analog of
αGalCer for NKT cell activation
iNKT cells were activated by αGalCer treatment if not indicated otherwise.
in the field of cancer treatment and in autoimmune and inflamma-
tory diseases (Table 1). Preclinical studies using αGalCer demon-
strated moderate therapeutic activity by activating DCs and pro-
viding Th-like functions, generating CD8+ cytotoxic T cell (CTL)
and antibody responses. Currently, more potent αGalCer analogs
for iNKT cell activation are under investigation (10–13). Applying
NKT cell immunization schemes in clinical settings is a promising
therapeutic opportunity, but requires detailed knowledge on how
iNKT cells activate DCs.
iNKT Cell Activation, Subsets, and
Cytokine Production
Most knowledge on NKT cell activation came from the use
of αGalCer, a strong and prototypical CD1-restricted agonist.
In the last years, additional microbial-derived glycolipid lig-
ands were identified, including α-glucuronosylceramides (from
Sphingomonas), cholesteryl α-glucoside (from Helicobacter), or
diacylglycerol-containing glycolipids (from Borrelia) (53, 54).
These lead to sustained iNKT cell activation with inflammatory
cytokine production that is independent of TLR stimulation, IL-
12, or the recognition of endogenous antigens, hence relying
only on engaging the invariant TCR. α-glucuronosylceramide
induces IFNγ and IL-4 release similar to αGalCer (55–57). Both
glycolipid antigens are structurally similar and can be recognized
by the majority of mouse and human iNKT cells (58). Syn-
thetic iNKT cell antigens have been and continue to be studied
extensively for potential therapeutic application (59). However,
iNKT cell activation may also promote allergic airway inflam-
mation, and their overstimulation can induce iNKT cell anergy
(1, 60).
Most microorganisms lack cognate iNKT cell antigens, hence
activation of these cells relies on cytokines, such as IL-12 or
IL-18, in conjunction with endogenous antigens. Even in the
absence of TCR stimulation, some bacterial and viral infections
induce a robust IL-12 response by DCs thereby activating iNKT
cells in vivo (61, 62). Indirect iNKT cell activation results in
the release of IFNγ but usually not IL-4 and is not restricted to
TLR (62–65).
Analogous to Th cells subsets, different NKT cell subsets
termed NKT1, NKT2, NKT17, NKTFH, and NKT10 subsets were
described with corresponding functionalities (66, 67). NKT17
cells produce the cytokines, IL-17 and IL-22, and are abundant in
the lymph nodes, lungs, and skin of mice with airway neutrophilia
induced by αGalCer (68). Recently, it was shown that iNKT17
cells are enriched in NOD mice, a mouse model for type I dia-
betes, which hint toward a possible role of those cells in disease
development (69). iNKT17 cells rely on IL-7 for homeostasis and
survival (70) and seem to require activation in the presence of
TGF-β and IL-1β (71). The recently described NKT10 subset
can dampen inflammatory responses by IL-10 production and
is enriched in adipose tissue, providing protection in obesity-
induced inflammation (72).
Dendritic Cell Maturation and CD8+ T Cell
Cross-Priming
Dendritic cells classically gather antigens in tissues and trans-
port them into lymphatic organs, where they orchestrate the
activation and differentiation of naïve CD8+ T cells into CTL.
Recent work showed that some DCs remain in tissues in order
to regulate immigrating effector T cell responses, which is impor-
tant in the defense against infections and may also promote
the progression of many immune-mediated diseases. The cross-
talk of myeloid cells with other immune cells, such as T cells
and innate lymphocytes, is especially important in this context.
Cellular encounters are orchestrated by chemokines, cytokines,
and cell surface molecules. Some DCs, especially the XCR1+ DC
subset, are specialized in cross-presentation, which allows the
presentation of extracellular antigens to activate CTL, a process
important for immunity against tumors, viruses, and intracel-
lular bacteria and for vaccination (73–76). Immunogenic cross-
presentation, also referred to as cross-priming, requires the pres-
ence of pathogen-derived molecules (PAMPs) and/or of spe-
cific Th cells or NKT cells that mature the cross-presenting DC
(77). This process is called “licensing,” a term introduced by
Lanzavecchia (78), and it aims at preventing unwanted immune
answers against innocuous or self antigens. Licensing was first
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described by Matzinger, Heath, and Melief (79–81), and classi-
cally is mediated by CD40 ligand provided by specific CD4+
helper T cells (Th). In addition to licensing, immunogenic T
cell priming requires the DCs to mature, a process that results
from sensing various PAMPs, including ligands for TLR, lectins,
intracellular nucleotide-binding oligomerization domain recep-
tors, or retinoic acid-induced genes (82–85). Major consequences
ofDCmaturation are the upregulation of costimulatorymolecules
like CD80 and CD86, CD40, of MHC II and the production
of pro-inflammatory cytokines, especially IL-12p70 and TNF.
These consequences partially can result also from CD40–CD40L
interactions, but it is not clearly defined how much DC licensing
and maturation functionally overlap. CD40–CD40L interactions
are not only crucial for upregulation of costimulatory molecules
but also for DC survival (86). Additionally, mature DCs produce
chemokines to attract other immune cells and to orchestrate the
ongoing immune response. In contrast to maturation-induced
upregulation ofMHC II, CD1 trafficking is differentially regulated
during DC maturation, and CD1 molecules are already expressed
on immature DCs. While human DCs express all classes of CD1
molecules, murine DCs express only CD1d (87), which is cru-
cial for DC–iNKT cell interactions. Trafficking studies showed
that antigen presentation by CD1d to iNKT cells might already
occur before DC maturation and MHC II presentation (88). This
notion hinted to a possible role of iNKT cells as immunological
helper cells.
iNKT Cells as Immunological Helper Cells
αGalCer was found to mediate CD40-dependent activation of
CTL by NKT cell-helped DC (89), directing attention to the adju-
vant activity for this agent. Furthermore, αGalCer also induced
resistance to tumors and intracellular pathogens (25). Com-
pared to CD40 ligation, LPS, and CpG, αGalCer induced equally
high levels of CD40, CD80, CD86, MHC II, and DEC205 in
CD11c+ CD8a+ and CD11c+ CD8a  DCs, but was unable to
induce DC maturation from bone marrow progenitors. Rather
than acting directly on DCs, αGalCer mediated DC maturation
through iNKT cells in aMyD88-independentmanner. Combining
αGalCer with CD40 stimulation caused DC to produce high
amounts of IL12p70, while LPS and CD40 stimulation showed
no such effect. IL12p70 production might explain the results of
another study (90), where the simultaneous administration of
OVA and αGalCer enhanced Th and CTL responses in an iNKT
cell-dependent manner. A close temporal association between
αGalCer and OVA-derived peptides and additional experiments
with antigen-loaded DCs led to the conclusion that αGalCer and
peptides must reach the same DC. Formal in vivo evidence for
such a tripartite cellular interaction was provided with the use of
bm1/CD1d bone marrow chimeras (91). In addition, there was
synergy when Th and iNKT help were combined. The means
by which iNKT cells license DCs are not fully understood but
in addition to providing CD40L to DCs, iNKT cells may act by
promoting cross-talk ofXCR1+DCs andplasmacytoidDC (92) or
by abundant cytokine production upon activation.Whether iNKT
cells play a role as helper cells when activated by less potent ligands
remains to be elucidated.
iNKT Cells Help in CTL and CD8+ Memory
T Cell Formation
The knowledge onmechanisms iNKT cells use to substitute CD4+
T cell help for antibody production, CTL generation, or mem-
ory formation is central for developing new vaccination strate-
gies. An unresolved question is why some groups observed NKT
cell-dependent reduction of CTL-mediated autoimmune diseases,
whereas NKT cell-licensed DC induced strong CTL responses
against tumors and viruses in other studies. The most obvious
difference is the use of a single low dose of αGalCer for induction
of protective CTL responses and the use of multiple doses or high
single doses of αGalCer to inhibit unwanted T cell responses (93).
In some clinical trials, αGalCer was used to treat cancer, and
human CD4+ iNKT cells expanded predominantly during early
stages (26). CD4+ iNKT cells can induce IL12p70 production
by DC and thereby Th1 polarization (93). Double negative (DN)
iNKTcells expanded later afterαGalCer treatment and can induce
apoptosis in αGalCer-loaded DC, thereby limiting the immune
response (26). Functional differences between iNKT cell subsets
in regards to cytokine production are evident both in mice and
humans (94), but the effects on DC maturation, apoptosis, and
CTL generation remain to be elucidated (Figure 1). A high fre-
quency of a DN iNKT cell subset and their potential to lyse DCs
may impair treatment of cancer patients and vaccination strate-
gies. The role of iNKT cells during viral infections and the use of
αGalCer as vaccine adjuvant in the context of influenza infections
have been reviewed recently in Ref. (14, 95). αGalCer increased
the levels of influenza-specific systemic IgG and mucosal IgA
antibodies, even in the absence of Th cells and antigen-specific
CTL responses (14, 95). In contrast, after combined iNKT cell
activation and influenza virus vaccination, an impaired CTL
response but enhanced memory CTL generation was seen (96).
In line with this, enhanced CTL memory differentiation during
viral infection was also shown previously (97). Another study
showed that iNKT cell enrichment in the CNS during Theiler’s
murine encephalomyelitis virus (TEMV) infection inhibited the
antiviral CTL response and delayed the accumulation of TEMV-
specific CTL. Also, the magnitude of the TEMV-specific CTL
response was impaired (98). CTL memory formation was not
assessed in that study. Co-administration of αGalCer with sub-
optimal doses of irradiated sporozoites or recombinant viruses
expressing a malaria antigen enhanced protective anti-malaria
immunity in mice, and co-administration of αGalCer with var-
ious immunogens enhanced antigen-specific CTL responses and
Th1 responses (99). In conclusion, vaccination with αGalCer as
adjuvant induced iNKT cell help for DCs, which promoted CTL
memory formation but impaired primary antigen-specific CTL
responses.
Before we can fully understand the mechanisms of iNKT cell
help in CTL formation and memory generation, it is crucial to
know how “help” influences CTL responses in general. Many
reports about Th help are available and most of them show a
diverse picture of the requirement for CD4+ T cell help in primary
and/or secondary infections. Th help seems to be crucial for the
clearance of some primary virus infections like HSV or influenza
that do not affect DCs directly (100, 101), while in some viral
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FIGURE 1 | iNKT cell–DC interactions after stimulation with
αGalCer. (A) Under optimal stimulatory conditions, iNKT cells produce
IL-4, large amounts of IFNγ and upregulate CD40L, thereby inducing
maturation in DC. DC maturation leads to increased costimulatory
capacity through upregulation of CD80 and CD86, of MHC molecules,
and by producing the pro-inflammatory cytokine, IL-12, and the
chemokine, CCL17. CCL17 attracts CCR4+ cells, including CD8+
T cells, which can be activated by the licensed DC. (B) Overstimulated
iNKT cells upregulate inhibitory receptors like CD94 and are incapable of
producing IFNγ. DC interacing with hyporesponsive iNKT cells cannot be
activated and do not induce CD8+ T cell activation. (C) Some activated
iNKT cells induce DC lysis rather than maturation by yet unknown
mechanisms. Proposed mechanisms suggest a role for TNFα, perforin,
Fas–FasL interactions, and even CD40–CD40L.
infections, Th help can be overcome (102). Additionally, CTL
responses against minor H antigens, soluble proteins, tumors, and
peptide-pulsed DC require Th help for the induction of optimal
primary responses (79, 103, 104). Some groups disagreed whether
Th help was needed during secondary responses for proper re-
expansion of CTL (105, 106) or whether Th help wasmerely a pre-
requisite during primary infections for CTL memory formation
(107). Additionally, Th help was dispensable for the expansion,
but not for the cytotoxic capacity of CTL in tuberculosis (108).
These differential observations may be explained not only by
the variance of pathogens and model antigens used but also
by different experimental setups. Moreover, Th dependency was
studied by using CD4 /  mice, MHC II /  mice, or CD4-
depleting antibodies, which are not biologically equivalent (109).
For example, CD4-depleting antibodies also deplete regulatory
T cells, CD4+ NKT cells, and CD4+ DCs. However, most older
studies agreed that the requirement for Th help is not a CTL-
intrinsic property but dependent on the infectious agent and
DC maturation. Given the huge discrepancies in studies on Th
help requirements, observations in a single model do not permit
general conclusions on how CD4+ help may be substituted by
iNKT cells. A deeper insight into CTL generation and memory
formation is required to allow predictions for the role of iNKT cell
help in CTL responses.
As reviewed previously in Ref.(110), CTL in primary responses
can be divided into short-lived effector cells (SLEC) that mostly
die off during the contraction phase and memory precursor cells
(MPEC) that received less stimulation but more survival signals
(111, 112). Even a single naive CTL can differentiate into a diverse
population of effector and memory cells (113, 114) by multiple
mechanisms, which have been reviewed in detail by Kaech and
Cui (115). Prolonged antigen exposure and pro-inflammatory
cytokines like IL-12 and IL-2 promote terminal differentiation
of CTL and induce superior cytotoxic capacities (116–118). NKT
cells may affect CTL differentiation other than Th cells, but this
hypothesis requires further experimental exploration.
iNKT Cells and Chemokines in CTL and
CD8+ T Cell Memory Formation
Chemokines play amajor role in orchestrating primary andmem-
ory CTL responses. During infections, CTL upregulated CXCR3,
which allowed them to enter peripheral tissues (119). Th help was
required for enhanced recruitment of CTL to the site of infec-
tion in some situations (120) by promoting CXCL9 and CXCL10
production, with CXCL9 being especially important for rapid
memory responses in the lymph node (121). Infections of the lung
and intestine showed no requirement of Th help for migration as
lung infections, e.g., by influenza induce on-site proliferation of
CTL rather than recruitment (122, 123) but Th cells promoted
development of lung-resident memory cells (124).
CXCR3 also drove CTL toward an effector fate rather than
memory fate (125). In line with this, CXCR3CCR5 double-
deficient mice showed a decreased contraction phase and har-
bored more memory CTL, which were unable to migrate into
tissues and to clear infections (126). In humans, CCR5 expression
was associated with effector memory T cells, whereas CCR7 was
predominantly expressed on naïve and central memory T cells
and CCR6 expression was found on early effector memory T cells
(127–129).
iNKT cell-helped DCs produced high amounts of CCL17,
thereby attracting CCR4+ lymphocytes (91). This contrasts
the situation in classical Th cell-dependent cross-priming,
where DCs produced CCR5 ligands to attract CTL for cross-
priming. These chemokines synergically guided CTL toward
those DCs that have presented relevant antigen to helper T cell
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subsets, and thereby facilitated the ensuing CTL response. Thus,
CCR4- and CCR5-binding chemokines have been described as a
new signal in T cell activation, distinct from signal 1, antigen, and
signal 2, costimulation (130).
CCR4 is traditionally considered to be associated with skin
homing Th2 and memory CD4+ T cells (131–134), but also with
the recruitment of Treg to the inflamed liver (135). Several studies
in humans showed increased CCR4 expression also on CTL in
cutaneous diseases (136–138). A CCR4+ CD8+ central memory
subset has been described that was generated in the presence of
IL-4 and produced IL4 and IL-13 upon restimulation (139). These
cells were not cytotoxic and produced little IFNγ, features associ-
ated with a so-called Tc2 subset (139, 140). Kondo and Takiguchi
showed that human CCR4+ CD8+ T cells expressed less effector
molecules like perforin or granzymes compared to CCR6+ early
effector memory T cells, but produced more TNFα and IL-4 than
CCR7+ naïve or central memory CD8+ T cells. They concluded
that CCR4+CD8+ T cells are a “little more differentiated than
CCR7+ central memory ones and less differentiated than CCR6+
early effector memory ones” and that they can migrate into sec-
ondary lymphoid organs where they mature after interacting with
DCs expressing CCR4 ligand (141). Since iNKT cells produce IL-
4 upon activation and induce CCL17 production by helped DC,
they might play a role in the development or restimulation of
CCR4+ CD8+ T cells. The physiological role of this subset in viral
infections and tumors remains to be elucidated.
Concluding Remarks
CD4-helped DCs and NKT cell-helped DCs provide various cos-
timulatory signals and cytokines deciding the fate of CD8+ T cells
toward effector or memory. However, the set of chemokines pro-
duced by NKT cell-helped DCs attract different subsets of naïve
or memory CD8+ T cells compared to chemokines produced by
Th-helped DCs. Dissecting the role of those CD8+ T cells subsets
in effector and memory responses directed against tumors and
viral infections may facilitate developing effective NKT cell-based
vaccines.
Acknowledgments
We thank Dr. Kristina Koch for help with artwork. This work
was supported by the Deutsche Forschungsgemeinschaft (grants
SFB704 and 645). EM is supported by the German National
Academic Foundation. CK is a member of the Excellence-Cluster
ImmunoSensation.
References
1. Parekh VV, Wilson MT, Van Kaer L. iNKT-cell responses to glycolipids. Crit
Rev Immunol (2005) 25(3):183–213. doi:10.1615/CritRevImmunol.v25.i3.20
2. BendelacA, Savage PB, Teyton L. The biology ofNKT cells.AnnuRev Immunol
(2007) 25:297–336. doi:10.1146/annurev.immunol.25.022106.141711
3. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-
dependent NKT cells. J Clin Invest (2004) 114(10):1379–88. doi:10.1172/
JCI23594
4. Kumar V, Delovitch TL. Different subsets of natural killer T cells may vary in
their roles in health and disease. Immunology (2014) 142(3):321–36. doi:10.
1111/imm.12247
5. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA.
Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic
binding groove. Science (1997) 277(5324):339–45. doi:10.1126/science.277.
5324.339
6. Porcelli SA. The CD1 family: a third lineage of antigen-presenting molecules.
Adv Immunol (1995) 59:1–98. doi:10.1016/S0065-2776(08)60629-X
7. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, et al.
Essential role of NKT cells producing IL-4 and IL-13 in the development of
allergen-induced airway hyperreactivity. Nat Med (2003) 9(5):582–8. doi:10.
1038/nm851
8. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, et al. Activa-
tion of natural killer T cells by alpha-galactosylceramide treatment prevents
the onset and recurrence of autoimmune Type 1 diabetes. Nat Med (2001)
7(9):1057–62. doi:10.1038/nm0901-1057
9. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of
human V(alpha)24 natural killer T cells. J Exp Med (2002) 195(5):637–41.
doi:10.1084/jem.20011908
10. Li X, Fujio M, ImamuraM,WuD, Vasan S,Wong CH, et al. Design of a potent
CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A
(2010) 107(29):13010–5. doi:10.1073/pnas.1006662107
11. Faveeuw C, Trottein F. Optimization of natural killer T cell-mediated
immunotherapy in cancer using cell-based and nanovector vaccines. Cancer
Res (2014) 74(6):1632–8. doi:10.1158/0008-5472.CAN-13-3504
12. Carreno LJ, Kharkwal SS, Porcelli SA. Optimizing NKT cell ligands as vaccine
adjuvants. Immunotherapy (2014) 6(3):309–20. doi:10.2217/imt.13.175
13. Padte NN, Li X, Tsuji M, Vasan S. Clinical development of a novel CD1d-
binding NKT cell ligand as a vaccine adjuvant. Clin Immunol (2011)
140(2):142–51. doi:10.1016/j.clim.2010.11.009
14. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. Alpha-
galactosylceramide can act as a nasal vaccine adjuvant inducing protective
immune responses against viral infection and tumor. J Immunol (2005)
175(5):3309–17. doi:10.4049/jimmunol.175.5.3309
15. Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice
from tuberculosis. Infect Immun (2002) 70(11):6302–9. doi:10.1128/IAI.70.11.
6302-6309.2002
16. Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, et al. Enhance-
ment of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-
galactosylceramide. Vaccine (2008) 26(15):1807–16. doi:10.1016/j.vaccine.
2008.02.002
17. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation
inhibits hepatitis B virus replication in vivo. J Exp Med (2000) 192(7):921–30.
doi:10.1084/jem.192.7.921
18. Kopecky-Bromberg SA, Fraser KA, PicaN, Carnero E,Moran TM, Franck RW,
et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza
virus vaccine. Vaccine (2009) 27(28):3766–74. doi:10.1016/j.vaccine.2009.03.
090
19. Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken
G, Nishi N, et al. Randomized placebo controlled phase I/II trial of alpha-
galactosylceramide for the treatment of chronic hepatitis C. J Hepatol (2007)
47(3):356–65. doi:10.1016/j.jhep.2007.04.018
20. Woltman AM, Ter Borg MJ, Binda RS, Sprengers D, von Blomberg BM,
Scheper RJ, et al. Alpha-galactosylceramide in chronic hepatitis B infection:
results from a randomized placebo-controlled phase I/II trial. Antivir Ther
(2009) 14(6):809–18. doi:10.3851/1295
21. Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, et al. A single intranasal
immunization with inactivated influenza virus and alpha-galactosylceramide
induces long-term protective immunity without redirecting antigen to the
central nervous system.Vaccine (2007) 25(28):5189–98. doi:10.1016/j.vaccine.
2007.04.081
22. Gonzalez-Aseguinolaza G, de Oliveira C, TomaskaM, Hong S, Bruna-Romero
O, Nakayama T, et al. Alpha-galactosylceramide-activated Valpha 14 natural
killer T cells mediate protection against murine malaria. Proc Natl Acad Sci
U S A (2000) 97(15):8461–6. doi:10.1073/pnas.97.15.8461
23. Kawakami K, Kinjo Y, Yara S, Koguchi Y, Uezu K, Nakayama T, et al.
Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide
results in development of Th1 response and local host resistance in mice
infected with Cryptococcus neoformans. Infect Immun (2001) 69(1):213–20.
doi:10.1128/IAI.69.1.213-220.2001
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3795
Gottschalk et al. NKT cells in cross-priming
24. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria
and melanoma metastases by a C-glycoside analogue of the natural killer
T cell ligand alpha-Galactosylceramide. J Exp Med (2003) 198(11):1631–41.
doi:10.1084/jem.20031192
25. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural
killer T cells by alpha-galactosylceramide rapidly induces the full maturation
of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4
and CD8 T cell immunity to a coadministered protein. J Exp Med (2003)
198(2):267–79. doi:10.1084/jem.20030324
26. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al.
Sustained expansion of NKT cells and antigen-specific T cells after injection
of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.
J Exp Med (2005) 201(9):1503–17. doi:10.1084/jem.20042592
27. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells
in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med
(2002) 196(1):119–27. doi:10.1084/jem.20020092
28. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I
study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000)
in patients with solid tumors. Clin Cancer Res (2002) 8(12):3702–9.
29. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M,
et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic
cells in patients with advanced and recurrent non-small cell lung cancer. Clin
Cancer Res (2005) 11(5):1910–7. doi:10.1158/1078-0432.CCR-04-1453
30. Kim D, Hung CF, Wu TC, Park YM. DNA vaccine with alpha-
galactosylceramide at prime phase enhances anti-tumor immunity after boost-
ing with antigen-expressing dendritic cells. Vaccine (2010) 28(45):7297–305.
doi:10.1016/j.vaccine.2010.08.079
31. Kim YJ, Ko HJ, Kim YS, Kim DH, Kang S, Kim JM, et al. Alpha-
galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum
of antitumor immunity. Int J Cancer (2008) 122(12):2774–83. doi:10.1002/ijc.
23444
32. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000,
a novel immunomodulator, and its antitumor activities. Oncol Res (1995)
7(10–11):529–34.
33. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, et al.
Combination therapy of in vitro-expanded natural killer T cells and alpha-
galactosylceramide-pulsed antigen-presenting cells in patients with recurrent
head and neck carcinoma. Cancer Sci (2009) 100(6):1092–8. doi:10.1111/j.
1349-7006.2009.01135.x
34. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A
phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured
peripheral blood mononuclear cells in patients with advanced and recurrent
non-small cell lung cancer. J Immunol (2009) 182(4):2492–501. doi:10.4049/
jimmunol.0800126
35. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic
activation of Valpha24+Vbeta11+ NKT cells in human subjects results in
highly coordinated secondary activation of acquired and innate immunity.
Blood (2004) 103(2):383–9. doi:10.1182/blood-2003-04-1155
36. Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, Rabbani
E, et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular
carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer (2003)
106(2):236–43. doi:10.1002/ijc.11201
37. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, et al.
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-
mediated immunotherapy. J Clin Invest (2004) 114(12):1800–11. doi:10.1172/
JCI22046
38. Teng MW, Westwood JA, Darcy PK, Sharkey J, Tsuji M, Franck RW, et al.
Combined natural killer T-cell based immunotherapy eradicates established
tumors in mice. Cancer Res (2007) 67(15):7495–504. doi:10.1158/0008-5472.
CAN-07-0941
39. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, et al.
Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells
administration to the nasal submucosa in unresectable or recurrent head and
neck cancer. Cancer Immunol Immunother (2008) 57(3):337–45. doi:10.1007/
s00262-007-0373-5
40. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The
natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune
diabetes in non-obese diabeticmice.NatMed (2001) 7(9):1052–6. doi:10.1038/
nm0901-1052
41. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M,
et al. Activation of natural killer T cells potentiates or prevents experimental
autoimmune encephalomyelitis. J Exp Med (2001) 194(12):1789–99. doi:10.
1084/jem.194.12.1789
42. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y, et al.
Activation of CD1d-restricted T cells protects NOD mice from developing
diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A (2001)
98(24):13838–43. doi:10.1073/pnas.251531798
43. Singh AK,Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, et al.
Natural killer T cell activation protectsmice against experimental autoimmune
encephalomyelitis. J Exp Med (2001) 194(12):1801–11. doi:10.1084/jem.194.
12.1801
44. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese
diabetic mice from developing diabetes. J Exp Med (2001) 194(3):313–20.
doi:10.1084/jem.194.3.313
45. Furlan R, Bergami A, Cantarella D, Brambilla E, Taniguchi M, Dellabona
P, et al. Activation of invariant NKT cells by alphaGalCer administration
protects mice fromMOG35-55-induced EAE: critical roles for administration
route and IFN-gamma. Eur J Immunol (2003) 33(7):1830–8. doi:10.1002/eji.
200323885
46. Zeng D, Liu Y, Sidobre S, KronenbergM, Strober S. Activation of natural killer
T cells in NZB/W mice induces Th1-type immune responses exacerbating
lupus. J Clin Invest (2003) 112(8):1211–22. doi:10.1172/JCI17165
47. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppres-
sion of collagen-induced arthritis by natural killer T cell activation with OCH,
a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum
(2004) 50(1):305–13. doi:10.1002/art.11489
48. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S. The involvement of
V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine
models. Arthritis Rheum (2005) 52(6):1941–8. doi:10.1002/art.21056
49. Kim HY, Kim HJ, Min HS, Kim S, Park WS, Park SH, et al. NKT cells
promote antibody-induced joint inflammation by suppressing transforming
growth factor beta1 production. J Exp Med (2005) 201(1):41–7. doi:10.1084/
jem.20041400
50. Kojo S, Seino K, Harada M, Watarai H, Wakao H, Uchida T, et al. Induction
of regulatory properties in dendritic cells by Valpha14 NKT cells. J Immunol
(2005) 175(6):3648–55. doi:10.4049/jimmunol.175.6.3648
51. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer
T cells in lupus and atherogenesis. Immunol Res (2006) 34(1):49–66. doi:10.
1385/IR:34:1:49
52. Yang JQ, Wen X, Liu H, Folayan G, Dong X, Zhou M, et al. Examining the
role of CD1d and natural killer T cells in the development of nephritis in a
genetically susceptible lupus model. Arthritis Rheum (2007) 56(4):1219–33.
doi:10.1002/art.22490
53. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural
killer T cells recognize glycolipids from pathogenic Gram-positive bacteria.
Nat Immunol (2011) 12(10):966–74. doi:10.1038/ni.2096
54. Chang YJ, Kim HY, Albacker LA, Lee HH, Baumgarth N, Akira S, et al.
Influenza infection in suckling mice expands an NKT cell subset that protects
against airway hyperreactivity. J Clin Invest (2011) 121(1):57–69. doi:10.1172/
JCI44845
55. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, et al. Recogni-
tion of bacterial glycosphingolipids by natural killer T cells. Nature (2005)
434(7032):520–5. doi:10.1038/nature03407
56. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C III, Zhou D, et al. Exoge-
nous and endogenous glycolipid antigens activate NKT cells during microbial
infections. Nature (2005) 434(7032):525–9. doi:10.1038/nature03408
57. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR, et al. Nat-
ural killer T cells recognize diacylglycerol antigens from pathogenic bacteria.
Nat Immunol (2006) 7(9):978–86. doi:10.1038/ni1380
58. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-
restricted and TCR-mediated activation of valpha14 NKT cells by glycosyl-
ceramides. Science (1997) 278(5343):1626–9. doi:10.1126/science.278.5343.
1626
59. Mallevaey T, SelvananthamT. Strategy of lipid recognition by invariant natural
killer T cells: ‘one for all and all for one’. Immunology (2012) 136(3):273–82.
doi:10.1111/j.1365-2567.2012.03580.x
60. Oki S, Miyake S. Invariant natural killer T (iNKT) cells in asthma: a novel
insight into the pathogenesis of asthma and the therapeutic implication of
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3796
Gottschalk et al. NKT cells in cross-priming
glycolipid ligands for allergic diseases. Allergol Int (2007) 56(1):7–14. doi:10.
2332/allergolint.R-06-137
61. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-
restricted natural killer T cell activation during microbial infection. Nat
Immunol (2003) 4(12):1230–7. doi:10.1038/ni1002
62. Wesley JD, Tessmer MS, Chaukos D, Brossay L. NK cell-like behavior
of Valpha14i NK T cells during MCMV infection. PLoS Pathog (2008)
4(7):e1000106. doi:10.1371/journal.ppat.1000106
63. Tyznik AJ, Tupin E, Nagarajan NA, Her MJ, Benedict CA, Kronenberg M.
Cutting edge: the mechanism of invariant NKT cell responses to viral danger
signals. J Immunol (2008) 181(7):4452–6. doi:10.4049/jimmunol.181.7.4452
64. Salio M, Speak AO, Shepherd D, Polzella P, Illarionov PA, Veerapen N, et al.
Modulation of human natural killer T cell ligands on TLR-mediated antigen-
presenting cell activation. Proc Natl Acad Sci U S A (2007) 104(51):20490–5.
doi:10.1073/pnas.0710145104
65. Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, Sheehan KC, et al.
Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic
cells requires type I interferon and charged glycosphingolipids. Immunity
(2007) 27(4):597–609. doi:10.1016/j.immuni.2007.08.017
66. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG,
et al. Differential antitumor immunity mediated by NKT cell subsets in vivo.
J Exp Med (2005) 202(9):1279–88. doi:10.1084/jem.20050953
67. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state produc-
tion of IL-4modulates immunity inmouse strains and is determined by lineage
diversity of iNKT cells. Nat Immunol (2013) 14(11):1146–54. doi:10.1038/ni.
2731
68. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, et al. Iden-
tification of an IL-17-producing NK1.1(neg) iNKT cell population involved
in airway neutrophilia. J Exp Med (2007) 204(5):995–1001. doi:10.1084/jem.
20061551
69. Li S, Joseph C, Becourt C, Klibi J, Luce S, Dubois-Laforgue D, et al. Potential
role of IL-17-producing iNKT cells in type 1 diabetes. PLoS One (2014)
9(4):e96151. doi:10.1371/journal.pone.0096151
70. Webster KE, Kim HO, Kyparissoudis K, Corpuz TM, Pinget GV, Uldrich AP,
et al. IL-17-producing NKT cells depend exclusively on IL-7 for homeostasis
and survival.Mucosal Immunol (2014) 7(5):1058–67. doi:10.1038/mi.2013.122
71. Monteiro M, Almeida CF, Agua-Doce A, Graca L. Induced IL-17-producing
invariant NKT cells require activation in presence of TGF-beta and IL-1beta.
J Immunol (2013) 190(2):805–11. doi:10.4049/jimmunol.1201010
72. Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, et al.
Adipose tissue invariant NKT cells protect against diet-induced obesity and
metabolic disorder through regulatory cytokine production. Immunity (2012)
37(3):574–87. doi:10.1016/j.immuni.2012.06.016
73. Schoenberger SP, van der Voort EI, Krietemeijer GM, Offringa R, Melief CJ,
Toes RE. Cross-priming of CTL responses in vivo does not require antigenic
peptides in the endoplasmic reticulum of immunizing cells. J Immunol (1998)
161(8):3808–12.
74. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-
infected non-haematopoietic cells requires presentation of exogenous antigen.
Nature (1999) 398(6722):77–80. doi:10.1038/18038
75. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells
cross-prime cytotoxic T cells in vivo. J Exp Med (2000) 192(12):1685–96.
doi:10.1084/jem.192.12.1685
76. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat
Rev Immunol (2010) 10(6):403–14. doi:10.1038/nri2780
77. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR,
et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell
immunity. Nat Immunol (2004) 5(11):1143–8. doi:10.1038/ni1129
78. Lanzavecchia A. Immunology. Licence to kill.Nature (1998) 393(6684):413–4.
doi:10.1038/30845
79. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a
CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate
CD4+ T cell help. J Exp Med (1997) 186(1):65–70. doi:10.1084/jem.186.1.65
80. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a
temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998)
393(6684):474–8. doi:10.1038/30989
81. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help
for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.Nature
(1998) 393(6684):480–3. doi:10.1038/31002
82. Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune
responses. Science (2001) 293(5528):253–6. doi:10.1126/science.1062060
83. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation
and apoptosis. Nat Rev Immunol (2003) 3(5):371–82. doi:10.1038/nri1086
84. Geijtenbeek TB, van Vliet SJ, Engering A, t Hart BA, van Kooyk Y. Self- and
nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol
(2004) 22:33–54. doi:10.1146/annurev.immunol.22.012703.104558
85. Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E,
et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern
recognition pathway for C type lectins. Immunity (2005) 22(4):507–17. doi:10.
1016/j.immuni.2005.03.004
86. Miga AJ, Masters SR, Durell BG, Gonzalez M, Jenkins MK, Maliszewski
C, et al. Dendritic cell longevity and T cell persistence is controlled by
CD154-CD40 interactions. Eur J Immunol (2001) 31(3):959–65. doi:10.1002/
1521-4141(200103)31:3<959::AID-IMMU959>3.0.CO;2-A
87. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev
Immunol (2007) 7(12):929–41. doi:10.1038/nri2191
88. Gelin C, Sloma I, Charron D,Mooney N. Regulation ofMHC II and CD1 anti-
gen presentation: from ubiquity to security. J Leukoc Biol (2009) 85(2):215–24.
doi:10.1189/jlb.0308206
89. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, et al. The
interface between innate and acquired immunity: glycolipid antigen presen-
tation by CD1d-expressing dendritic cells to NKT cells induces the differ-
entiation of antigen-specific cytotoxic T lymphocytes. Int Immunol (2000)
12(7):987–94. doi:10.1093/intimm/12.7.987
90. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, et al. NKT cells
enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through
direct interaction with dendritic cells. J Immunol (2003) 171(10):5140–7.
doi:10.4049/jimmunol.171.10.5140
91. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer
U, et al. Alternative cross-priming through CCL17-CCR4-mediated attraction
of CTLs toward NKT cell-licensed DCs. Nat Immunol (2010) 11(4):313–20.
doi:10.1038/ni.1848
92. Shimizu K, AsakuraM, Shinga J, Sato Y, Kitahara S, Hoshino K, et al. Invariant
NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conven-
tional DCs for efficient memory CD8+ T cell induction. J Immunol (2013)
190(11):5609–19. doi:10.4049/jimmunol.1300033
93. Liu TY, Uemura Y, Suzuki M, Narita Y, Hirata S, Ohyama H, et al. Dis-
tinct subsets of human invariant NKT cells differentially regulate T helper
responses via dendritic cells. Eur J Immunol (2008) 38(4):1012–23. doi:10.
1002/eji.200737838
94. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie
BS, et al. Diverse cytokine production by NKT cell subsets and identification
of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci
U S A (2008) 105(32):11287–92. doi:10.1073/pnas.0801631105
95. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, et al. Invariant
NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci
U S A (2007) 104(10):3984–9. doi:10.1073/pnas.0700191104
96. Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, et al.
Combined NKT cell activation and influenza virus vaccination boosts mem-
ory CTL generation and protective immunity. Proc Natl Acad Sci U S A (2009)
106(9):3330–5. doi:10.1073/pnas.0813309106
97. Reilly EC, Thompson EA, Aspeslagh S, Wands JR, Elewaut D, Brossay L. Acti-
vated iNKT cells promote memory CD8+ T cell differentiation during viral
infection. PLoS One (2012) 7(5):e37991. doi:10.1371/journal.pone.0037991
98. Mars LT, Mas M, Beaudoin L, Bauer J, Leite-de-Moraes M, Lehuen A, et al.
Invariant NKT cells regulate the CD8 T cell response during Theiler’s virus
infection. PLoS One (2014) 9(1):e87717. doi:10.1371/journal.pone.0087717
99. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg
J, Kronenberg M, et al. Natural killer T cell ligand alpha-galactosylceramide
enhances protective immunity induced by malaria vaccines. J Exp Med (2002)
195(5):617–24. doi:10.1084/jem.20011889
100. Jennings SR, Bonneau RH, Smith PM, Wolcott RM, Chervenak R. CD4-
positive T lymphocytes are required for the generation of the primary but
not the secondary CD8-positive cytolytic T lymphocyte response to herpes
simplex virus in C57BL/6 mice. Cell Immunol (1991) 133(1):234–52. doi:10.
1016/0008-8749(91)90194-G
101. Riberdy JM, Christensen JP, BranumK, Doherty PC. Diminished primary and
secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3797
Gottschalk et al. NKT cells in cross-priming
Ig(-/-) mice. J Virol (2000) 74(20):9762–5. doi:10.1128/JVI.74.20.9762-9765.
2000
102. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoen-
berger SP. CD4+ T cells are required for secondary expansion and mem-
ory in CD8+ T lymphocytes. Nature (2003) 421(6925):852–6. doi:10.1038/
nature01441
103. Husmann LA, Bevan MJ. Cooperation between helper T cells and cytotoxic
T lymphocyte precursors. Ann N Y Acad Sci (1988) 532:158–69. doi:10.1111/
j.1749-6632.1988.tb36335.x
104. Guerder S, Matzinger P. A fail-safe mechanism for maintaining self-tolerance.
J Exp Med (1992) 176(2):553–64. doi:10.1084/jem.176.2.553
105. Di Rosa F, Matzinger P. Long-lasting CD8 T cell memory in the absence of
CD4 T cells or B cells. J ExpMed (1996) 183(5):2153–63. doi:10.1084/jem.183.
5.2153
106. Bourgeois C, Veiga-FernandesH, Joret AM, Rocha B, Tanchot C. CD8 lethargy
in the absence of CD4 help. Eur J Immunol (2002) 32(8):2199–207. doi:10.
1002/1521-4141(200208)32:8<2199::AID-IMMU2199>3.0.CO;2-L
107. Marzo AL, Vezys V, Klonowski KD, Lee SJ, Muralimohan G, Moore M, et al.
Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol
(2004) 173(2):969–75. doi:10.4049/jimmunol.173.2.969
108. SerbinaNV, Lazarevic V, Flynn JL. CD4(+) T cells are required for the develop-
ment of cytotoxic CD8(+) T cells duringMycobacterium tuberculosis infection.
J Immunol (2001) 167(12):6991–7000. doi:10.4049/jimmunol.167.12.6991
109. Tyznik AJ, Sun JC, Bevan MJ. The CD8 population in CD4-deficient mice is
heavily contaminated with MHC class II-restricted T cells. J Exp Med (2004)
199(4):559–65. doi:10.1084/jem.20031961
110. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system.
Immunity (2011) 35(2):161–8. doi:10.1016/j.immuni.2011.07.010
111. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck
CD, et al. Signals required for programming effector and memory devel-
opment by CD8+ T cells. Immunol Rev (2006) 211:81–92. doi:10.1111/j.
0105-2896.2006.00382.x
112. Parish IA, Kaech SM. Diversity in CD8(+) T cell differentiation. Curr Opin
Immunol (2009) 21(3):291–7. doi:10.1016/j.coi.2009.05.008
113. Stemberger C, Neuenhahn M, Buchholz VR, Busch DH. Origin of CD8+
effector and memory T cell subsets. Cell Mol Immunol (2007) 4(6):399–405.
114. Gerlach C, van Heijst JW, Swart E, Sie D, Armstrong N, Kerkhoven RM, et al.
One naive T cell,multiple fates inCD8+T cell differentiation. J ExpMed (2010)
207(6):1235–46. doi:10.1084/jem.20091175
115. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+
T cell differentiation. Nat Rev Immunol (2012) 12(11):749–61. doi:10.1038/
nri3307
116. Curtsinger JM, Johnson CM, Mescher MF. CD8 T cell clonal expansion
and development of effector function require prolonged exposure to antigen,
costimulation, and signal 3 cytokine. J Immunol (2003) 171(10):5165–71.
doi:10.4049/jimmunol.171.10.5165
117. Pearce EL, Shen H. Generation of CD8 T cell memory is regulated by IL-12.
J Immunol (2007) 179(4):2074–81. doi:10.4049/jimmunol.179.4.2074
118. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A.
Interleukin-2 and inflammation induce distinct transcriptional programs that
promote the differentiation of effector cytolytic T cells. Immunity (2010)
32(1):79–90. doi:10.1016/j.immuni.2009.11.012
119. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res (2011)
317(5):620–31. doi:10.1016/j.yexcr.2010.12.017
120. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobi-
lization to virus-infected tissue requires CD4(+) T-cell help. Nature (2009)
462(7272):510–3. doi:10.1038/nature08511
121. Kastenmuller W, Brandes M, Wang Z, Herz J, Egen JG, Germain RN. Periph-
eral prepositioning and local CXCL9 chemokine-mediated guidance orches-
trate rapid memory CD8+ T cell responses in the lymph node. Immunity
(2013) 38(3):502–13. doi:10.1016/j.immuni.2012.11.012
122. Bedoui S, Gebhardt T. Interaction between dendritic cells and T cells during
peripheral virus infections: a role for antigen presentation beyond lymphoid
organs? Curr Opin Immunol (2011) 23(1):124–30. doi:10.1016/j.coi.2010.11.
001
123. McGill J, Legge KL. Cutting edge: contribution of lung-resident T cell prolif-
eration to the overall magnitude of the antigen-specific CD8 T cell response
in the lungs following murine influenza virus infection. J Immunol (2009)
183(7):4177–81. doi:10.4049/jimmunol.0901109
124. Laidlaw BJ, Zhang N, Marshall HD, Staron MM, Guan T, Hu Y, et al. CD4+
T cell help guides formation of CD103+ lung-resident memory CD8+ T cells
during influenza viral infection. Immunity (2014) 41(4):633–45. doi:10.1016/
j.immuni.2014.09.007
125. Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, et al. Chemokine
receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effec-
tor cells leading to memory degeneration. J Exp Med (2011) 208(8):1605–20.
doi:10.1084/jem.20102101
126. Kohlmeier JE, Reiley WW, Perona-Wright G, Freeman ML, Yager EJ, Con-
nor LM, et al. Inflammatory chemokine receptors regulate CD8(+) T cell
contraction and memory generation following infection. J Exp Med (2011)
208(8):1621–34. doi:10.1084/jem.20102110
127. Tomiyama H, Matsuda T, Takiguchi M. Differentiation of human CD8(+)
T cells from a memory to memory/effector phenotype. J Immunol (2002)
168(11):5538–50. doi:10.4049/jimmunol.168.11.5538
128. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory
T cell subsets: function, generation, and maintenance. Annu Rev Immunol
(2004) 22:745–63. doi:10.1146/annurev.immunol.22.012703.104702
129. Tomiyama H, Takata H, Matsuda T, Takiguchi M. Phenotypic classifica-
tion of human CD8+ T cells reflecting their function: inverse correlation
between quantitative expression of CD27 and cytotoxic effector function. Eur
J Immunol (2004) 34(4):999–1010. doi:10.1002/eji.200324478
130. Bousso P, Albert ML. Signal 0 for guided priming of CTLs: NKT cells do it too.
Nat Immunol (2010) 11(4):284–6. doi:10.1038/ni0410-284
131. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CGA.
Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+
lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol (2000)
115(4):640–6. doi:10.1046/j.1523-1747.2000.00115.x
132. Nakatani T, Kaburagi Y, Shimada Y, Inaoki M, Takehara K, Mukaida N, et al.
CCR4 memory CD4+ T lymphocytes are increased in peripheral blood and
lesional skin from patients with atopic dermatitis. J Allergy Clin Immunol
(2001) 107(2):353–8. doi:10.1067/mai.2001.112601
133. Kusumoto M, Xu B, Shi M, Matsuyama T, Aoyama K, Takeuchi T. Expression
of chemokine receptor CCR4 and its ligands (CCL17 and CCL22) in murine
contact hypersensitivity. J Interferon Cytokine Res (2007) 27(11):901–10.
doi:10.1089/jir.2006.0064
134. Gehad A, Al-Banna NA, Vaci M, Issekutz AC, Mohan K, Latta M, et al. Differ-
ing requirements for CCR4, E-selectin, and alpha4beta1 for the migration of
memory CD4 and activated T cells to dermal inflammation. J Immunol (2012)
189(1):337–46. doi:10.4049/jimmunol.1102315
135. Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of
lymphocytes to the liver. Dig Dis (2010) 28(1):31–44. doi:10.1159/000282062
136. Teraki Y, Miyake A, Takebayashi R, Shiohara T. Homing receptor and
chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp
Dermatol (2004) 29(6):658–63. doi:10.1111/j.1365-2230.2004.01638.x
137. Wenzel J, Henze S, Worenkamper E, Basner-Tschakarjan E, Sokolowska-
Wojdylo M, Steitz J, et al. Role of the chemokine receptor CCR4 and its
ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte
recruitment in cutaneous lupus erythematosus. J Invest Dermatol (2005)
124(6):1241–8. doi:10.1111/j.0022-202X.2005.23755.x
138. Seneviratne SL, Black AP, Jones L, Bailey AS, Ogg GS. The role of skin-homing
T cells in extrinsic atopic dermatitis. QJM (2007) 100(1):19–27. doi:10.1093/
qjmed/hcl132
139. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation
potential of human CD8+ memory T-cell subsets in response to anti-
gen or homeostatic cytokines. Blood (2003) 101(11):4260–6. doi:10.1182/
blood-2002-11-3577
140. Le Gros G, Erard F. Non-cytotoxic, IL-4, IL-5, IL-10 producing CD8+ T cells:
their activation and effector functions. Curr Opin Immunol (1994) 6(3):453–7.
doi:10.1016/0952-7915(94)90127-9
141. Kondo T, Takiguchi M. Human memory CCR4+CD8+ T cell subset has
the ability to produce multiple cytokines. Int Immunol (2009) 21(5):523–32.
doi:10.1093/intimm/dxp019
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Gottschalk, Mettke and Kurts. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3798
